← Human Trials & Peer-Reviewed Studies
Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate once weekly or placebo, concomitant with calcium and vitamin D supplementation.
Plain-language guide to PMID 24146170 (2014): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc, osteoporosis and bone density.
Key Facts
- PMID
- 24146170
- Journal
- Gut
- Year
- 2014
- Study type
- Randomized Controlled Trial
- Authors
- van Bodegraven AA et al. (17 authors)
- DOI
- 10.1136/gutjnl-2013-305523
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of osteoporosis and bone density.
Osteoporosis and fractures are frequently encountered in patients with Crohn's disease.
Who Took Part
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
This double-blind, placebo-controlled randomised trial of risedronate with calcium and vitamin D supplementation was performed in osteopenic Crohn's disease patients.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.
A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.
Disease characteristics and activity and bone turnover markers were assessed at all visits; dual x-ray absorptiometry was performed at baseline, 12 and 24 months; radiographs of the spine at baseline and 24 months.
What Was Measured
Topics PubMed links to this paper include Absorptiometry, Photon, Bone Density, Bone Density Conservation Agents, Bone Diseases, Metabolic, Calcium, Crohn Disease and Dietary Supplements.
Author keywords: BONE MINERAL DENSITY, CLINICAL TRIALS, CROHN'S DISEASE and OSTEOPOROSIS.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in people with osteoporosis and bone density.
The abstract goes on to report its results in about 10 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2014 (Gut), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, Osteoporosis and bone density research.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.